High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment

Web  |  www.medsci.org | Nov 19, 2009

If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment options, because prostate cancer is not very sensitive to cytostatic agents. Temozolomide (TMZ) as an orally applicable chemotherapeutic substance has been proven to be effective and well tolerated with

http://www.medsci.org/v06p0338.htm

The Hypertext Guide to Prostate Cancer Cáncer de próstata: la guía en hipertexto O Guia...

The Hypertext Guide to Prostate Cancer Cáncer de próstata: la guía en hipertexto O Guia Hipertexto de Câncer de Próstata

http://www.hypertext.org/

Population-based study of long-term survival in patients with clinically localised prostate cancer

News  |  www.thelancet.com

Population-based study of long-term survival in patients with clinically localised prostate cancer. By - Grace L Lu-Yao PhD, Dr Siu-Long Yao MD

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)09380-4

Brachytherapy by Prostate Seed Institute, has been recognized as a “High Value” technology

Press Release  |  www.prlog.org | May 2, 2009

Brachytherapy by Prostate Seed Institute, has been recognized as a “High Value” technology. Prostate Seed Institute, a Texas based prostate cancer treatment clinic, has been recognized for Brachytherapy treatment by the Institute for Clinical and Economic Review (ICER).

http://www.prlog.org/10228454-brachytherapy-by-prostate-seed-institute-has-been-recognized-as-high-value-technology.html

Targeted Therapeutics for Chronic Diseases :ChemGenex Pharmaceuticals

Management Team Board of Directors Scientific Advisory Board Clinical Advisors RD Leaders Targeted Medicine Strategic Alliances Research Ethics Our History Omacetaxine mepesuccinate Quinamed® CXS-299 Cancer Discovery Program Drug Discovery & Preclinical Development Genomic Clinical Development

http://www.chemgenex.com/

New Finding Suggests Prostate Biopsy is Not Always Necessary

Web  |  www.cli-online.com

These "non-cancer" elevations in PSA could cause many men to be biopsied unnecessarily, which often leads to unnecessary treatment.

http://www.cli-online.com/index.php?id=2510&tx_ttnews[tt_news]=923&cHash=65536

Autopsy study links prostate cancer to single rogue cell

News  |  www.news-medical.net | Apr 16, 2009

One cell...one initial set of genetic changes - that's all it takes to begin a series of events that lead to metastatic cancer. Now, Johns Hopkins experts have tracked how the cancer process began in 33 men with prostate cancer who died of the disease. Culling information from autopsies, their

http://www.news-medical.net/?id=48427

ProstateLine - Prostate cancer information and news provided by AstraZeneca

Welcome to ProstateLine.com, an international educational resource for healthcare professionals, patients and carers with an interest in prostate cancer, provided by AstraZeneca. The information on this website is not intended to replace the advice of a qualified health professional.

http://www.prostateline.com/

Traits of Aggressive Form of Prostate Cancer Discovered

News  |  www.dddmag.com

Researchers led by a team at the Michigan Center for Translational Pathology University of Michigan Health System have identified traits of an aggressive type of prostate cancer that occurs in about 10 percent of men who have the disease.

http://www.dddmag.com/News-Prostate-Cancer-Traits-Discovered.aspx

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival

Press Release  |  www.prnewswire.com | Nov 4, 2009

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival.

http://www.prnewswire.com/news-releases/long-term-outcomes-data-validates-the-utility-of-prostascint-in-guiding-targeted-prostate-cancer-treatment-and-predicting-disease-free-survival-69063882.html